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Abstract
Hepatocellular carcinoma (also termed hepatocarcinoma) is the third cancer-related cause 
of death worldwide. To our knowledge, markers such as α-fetoprotein display poor perfor-
mance in the early diagnosis and prognosis prediction of hepatocarcinoma. MicroRNAs are 
an evolutionarily conserved class of small noncoding single-stranded RNA typically consist-
ing of 18–24 nucleotides. They have been reported to act as tumor suppressors or oncogenes 
via reversely regulating gene expression. Recent evidence has revealed that microRNAs, 
especially in body fluids such as the blood and urine, display important diagnostic and prog-
nostic potential for hepatocarcinoma. Here, we reviewed currently available data on microR-
NAs and hepatocarcinoma, with emphasis on the biogenesis and function of microRNAs 
and their potential diagnostic and prognostic value for hepatocarcinoma. We also discussed 
the clinical utility perspectives of microRNAs in hepatocarcinoma and possible challenges.
Keywords: hepatocarcinoma, microRNA, diagnosis, prognosis
1. Introduction
Hepatocarcinoma, also termed as hepatocellular carcinoma (HCC) or liver carcinoma, is the most 
common primary liver malignant disease in adults [1]. One of the most striking features of this 
malignant tumor is the wide variation in its incidence in different parts of the world. In areas of 
high incidence, such as China, hepatocarcinoma is among the leading cause of cancer-correlated 
deaths in recent years, with an annual incidence of approximately 40 per 100,000 [2, 3]. However, 
the countries in the low incidence, such as the USA, have only 2.3% of cancer-related deaths in 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
past decades. Globally, hepatocarcinoma is the fifth most common cancer among males and the 
eighth most common among females [1]. Furthermore, the incidence of this tumor generally 
increases with age, although there are geographic and gender differences. The precise reasons for 
this difference is not known, but growing evidence has exhibited that multiple factors including 
chronic viral hepatitis B (HBV) and C (HCV), aflatoxin (such as aflatoxin B1) exposure, hepatic 
cirrhosis, obesity, diabetes, and vitamin D deficiency play an important role [4–6]. Although the 
molecular mechanism of hepatocarcinoma has been unclear, these hepatocarcinoma patients 
with early diagnosis often have good prognosis with more than 50% of five overall survival rate 
[6]. This is mainly because they benefit from the curative treatment such as curative resection and 
orthotropic liver transplantation [6]. However, if patients are lately diagnosed, the cumulative 
5-year survival rate remarkably reduces to less than 10%, and tumor recurrence risk noticeably 
increases (about 70–80% of 5-year recurrence rate). Thus, it is very urgent to identify specific and 
sensitive markers for early diagnosing hepatocarcinoma at a curative stage, monitoring recur-
rence of tumor, and predicting prognosis of tumor [6].
Currently, the early diagnosis of hepatocarcinoma is based on the following two classes of 
methods: imaging examination which mainly consists of ultrasonography, magnetic reso-
nance imaging, and computed tomography and serological tests such as serous α-fetoprotein 
(AFP) [4, 7]. Although advances in imaging technologies have significantly improved the 
early screening of hepatocarcinoma, these methods are so costly and unsatisfactory in early 
diagnosis that is not suitable for daily clinical practice [4, 7]. About serological methods, AFP 
is the most widely utilized marker for the diagnosis and prognosis prediction of hepatocar-
cinoma. However, this biomarker is limited because of its modest accuracy (with sensitivity 
of 40–65% and specificity of 87–96%) and about 30–40% of the false-negative rate for patients 
with early-stage hepatocarcinoma [8]. Additionally, serum AFP levels of some benign hepatic 
lesions, such as liver nodular hyperplasia, inflammation lesions of liver, and liver fibrotic cir-
rhosis, may give false-positive results [8]. Therefore, the reliability of this biomarker to deter-
mine hepatocarcinoma is inadequate because of its low sensitivity and specificity.
Emerging evidence has exhibited a correlation between dysregulation of microRNAs and 
development of hepatocarcinoma. Particularly, microRNAs are characterized by high stabil-
ity in body fluids (including the blood and urine) and tissue specific in expression patterns, 
indicative of microRNAs in body fluids acting as potentially novel and ideal biomarkers for 
hepatocarcinoma diagnosis and prognosis prediction [8–16].
This review attempts to briefly review currently available data on microRNAs and hepatocar-
cinoma, with emphasis on (1) the biogenesis and function of microRNA, (2) potential diagnos-
tic and prognostic value for hepatocarcinoma, and (3) the different value for hepatocarcinoma 
induced by different causes. Additionally, we summarized the clinical applicative perspec-
tives and potential challenges of microRNAs in hepatocarcinoma.
2. MicroRNA biogenesis and function
Previous several reports have thoroughly reviewed biogenesis and function of microRNAs 
[8, 11, 17–29]. In brief, microRNAs are an evolutionarily conserved class of small noncoding 
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 single-stranded RNA typically consisting of 18–24 nucleotides. Originally, they are first tran-
scribed by the RNA polymerase enzyme II into a kind of primary production named as primary 
microRNA that is characterized by long nucleotide sequences, 5′-cap structure, and 3′-poly-A 
tail, resembling protein-coding mRNAs. Then, primary microRNAs form a hairpin-shaped stem-
loop structure and are processed into microRNA precursors (usually containing 60–70 nucleo-
tides) by the microprocessor complex (consisting of DGCR8/Pasha and Drosha). After that, their 
precursors are transported to the cytoplasm and treated into a short double-strand duplex struc-
ture by another RNase endonuclease III (also called Dicer). Finally, the duplex structure (also 
called microRNA-microRNA*) is unwound into mature microRNAs by helicases. To date, it has 
been identified that there are more than 1800 microRNAs in the mammalian genome (miRData-
base) (Figure 1) [30]. Functionally, microRNAs are involved in regulating the expression of their 
Figure 1. Biosynthesis and functions of microRNA. In the nucleus, the microRNA genes are transcribed into primary 
microRNAs by RNA polymerase II (Pol II). The primary microRNAs are then cleaved by Drosha and DGCR8 and 
produce their precursor molecules (also named as precursor microRNA). After that, the precursor molecules are 
transported to the cytoplasm by Exportin-5 and Ran-GTP and undergo final processing step including the cleavage by 
Dicer and the formation of stem-loop duplex molecule structure which contains the single-stranded mature microRNA 
molecule and a microRNA* fragment. Finally, the duplex molecule structure is incorporated into the RNA-induced 
silencing complex (RISC), the microRNA* fragments are degraded, and mature microRNA molecules are formed. The 
mature microRNAs can display genic regulation role via recognizing and binding to the 3′-untranslated region of their 
target genes’ mRNAs. Note: This figure is plotted according to ScienceSlides (version#2016).
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targeting genes via recognizing and integrating into the 3′-untranslated region of these genes’ 
mRNAs. On the basis of perfect or imperfect base-base complementarity of microRNAs-their tar-
geting mRNA binding, one microRNA specifically regulates the expression of multiple mRNAs, 
and at the same time, one mRNA might be inhibited by multiple microRNAs. This indicates the 
specificity and diversity of microRNAs regulating gene expression. In the past decades, microR-
NAs are emerged as important players in a very wide range of physiological processes includ-
ing cell differentiation, cell proliferation and apoptosis, cycle regulation, survival, detoxification, 
physiological timing, metabolism, angiogenesis, hormone secretion, and DNA damage repair 
(Figure 1). Furthermore, growing evidence has shown that microRNAs can also display a role in 
the etiology and pathogenesis of various cancers by targeting many oncogenes or tumor inhibi-
tive genes (Figure 1) [24, 27, 29–32]. Recent several reports have exhibited that some microRNAs 
involve in the tumorigenesis and procession of hepatocarcinoma and may become new potential 
markers for hepatocarcinoma diagnosis and prognosis [24, 27, 29, 31, 32].
3. MicroRNAs as novel biomarkers for hepatocarcinoma diagnosis
3.1. Diagnostic potential of single microRNA for hepatocarcinoma
With increasing incidence and death rate of hepatocarcinoma, it is very expected to iden-
tify one or several diagnostic biomarkers (with both high sensitivity and specificity) such as 
microRNAs for this malignancy. Growing evidence has shown that the expression change of 
all microRNAs in the peripheral blood may have a unique advantage because they exhibit tis-
sue specificity and relative stability and can also provide some specific cues for early and small 
hepatocarcinoma [8–14]. Until now, more than 30 circulating microRNAs have been identi-
fied to have diagnostic potential for hepatocarcinoma (Table 1). For example, microRNA-122 
has been reported as a hepatic-specific microRNA, accounting for 70% of the total microR-
NAs in hepatic tissues. This microRNA, a high conservative microRNA between vertebrate 
species, is indicative of a regulator of fatty acid metabolism and playing a critical role in 
liver homeostasis and tumorigenesis [19, 33, 34]. Increasing evidence has shown that elevated 
serum amount of microRNA-122 is positively associated with the severity of hepatic diseases 
including hepatitis, fatty- and alcohol-related liver damage, and drug-induced hepatotoxicity 
[35–39]. Interestingly, this increasing serum expression of microRNA-122 is noticeable and 
indicated that it could serve as a potential biomarker for the detection of patients with hepa-
tocarcinoma from healthy controls with about 85% of the area under the receiver operating 
characteristic curve (AUC), 80% of sensitivity, and 80% of specificity [40, 41]. These results 
indicate that the dysregulated miR-122 in the peripheral blood may be used as a potential 
marker for hepatocarcinoma diagnosis. Results from retrospective studies have suggested 
that the microRNA-200 family (consisting of microRNA-200a and microRNA -200b) is also 
a promising biochemical biomarker for hepatocarcinoma diagnosis because of its deregu-
lation during the development of both hepatic fibrosis and hepatocarcinoma [42, 43]. The 
elevated plasma levels of microRNA-21 can distinguish patients with hepatocarcinoma from 
cases with chronic hepatitis (with 61.1% of sensitivity and 83.3% of specificity) or healthy 
controls (the corresponding sensitivity and specificity are 87.3 and 92.0%, respectively) [44]. 
This suggests that this biomarker may have higher diagnostic potential than AFP. Some 
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MicroRNAs Source Diagnostic relevance Expression level AUC 
(95% CI)
Sen 
(%)
Spe 
(%)
Refs
miR-12 Serum HCCs (n = 101) vs. HCs 
(n = 89)
Upregulated 0.87 
(0.81–0.93)
84.0 75.3 [41]
miR-122 Serum HCCs (n = 101) vs. HCs 
(n = 89)
Upregulated 0.79 
(0.71–0.86)
70.7 69.1 [41]
miR-223 Serum HCCs (n = 101) vs. CHCs 
(n = 89)
Upregulated 0.86 
(0.80–0.92)
80.0 76.5 [41]
miR-12 Serum HCCs (n = 101) vs. HCs 
(n = 48)
Upregulated 0.91 
(0.84–0.97)
80.0 95.6 [41]
miR-122 Serum HCCs (n = 101) vs. HCs 
(n = 48)
Upregulated 0.93 
(0.88–0.98)
80.0 91.2 [41]
miR-223 Serum HCCs (n = 101) vs. HCs 
(n = 48)
Upregulated 0.88 
(0.81–0.94)
80.0 75.0 [41]
miR-122 Serum HCCs (n = 70) vs. HCs 
(n = 34)
Upregulated 0.87 
(0.79–0.95)
81.6 83.3 [40]
miR-122 Serum HCCs (n = 70) vs. CHCs 
(n = 45)
Upregulated 0.63 
(0.52–0.74)
77.6 57.8 [40]
miR-21 Plasma HCCs (n = 126) vs. HCs 
(n = 50)
Upregulated 0.77 61.1 83.3 [44]
miR-21 Plasma HCCs (n = 126) vs. CHCs 
(n = 30)
Upregulated 0.95 87.3 92.0 [44]
miR-143 Serum HCCs (n = 95) vs. CTLs 
(n = 245)
Upregulated 0.80 
(0.68–0.92)
73.0 83.0 [46]
miR-215 Serum HCCs (n = 95) vs. CTLs 
(n = 245)
Upregulated 0.82 
(0.72–0.97)
80.0 91.0 [46]
miR-10b Serum HCCs (n = 27) vs. HCs 
(n = 50)
Upregulated 0.85 
(0.76–0.94)
/ / [51]
miR-10b Serum HCCs (n = 27) vs. CLDs 
(n = 31)
Upregulated 0.73 
(0.60–0.86)
/ / [51]
miR-106b Serum HCCs (n = 27) vs. HCs 
(n = 50)
Upregulated 0.82 
(0.72–0.91)
/ / [51]
miR-106b Serum HCCs (n = 27) vs. CLDs 
(n = 31)
Upregulated 0.71 
(0.57–0.84)
/ / [51]
miR-181a Serum HCCs (n = 27) vs. HCs 
(n = 50)
Upregulated 0.89 
(0.81–0.97)
/ / [51]
miR-181a Serum HCCs (n = 27) vs. CLDs 
(n = 31)
Upregulated 0.81 
(0.70–0.92)
/ / [51]
miR-206 Serum HCCs (n = 261) vs. HCs 
(n = 173)
Upregulated 0.62 
(0.55–0.68)
48.1 78.8 [52]
miR-143-3p Serum HCCs (n = 261) vs. HCs 
(n = 173)
Upregulated 0.76 
(0.70–0.80)
68.1 83.3 [52]
miR-433-3p Serum HCCs (n = 261) vs. HCs 
(n = 173)
Upregulated 0.74 
(0.67–0.80)
79.3 64.4 [52]
miR-1228-5p Serum HCCs (n = 261) vs. HCs 
(n = 173)
Upregulated 0.55 
(0.44–0.60)
79.3 27.8 [52]
miR-199a-5p Serum HCCs (n = 261) vs. HCs 
(n = 173)
Downregulated 0.64 
(0.57–0.71)
59.3 66.7 [52]
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MicroRNAs Source Diagnostic relevance Expression level AUC 
(95% CI)
Sen 
(%)
Spe 
(%)
Refs
miR-122-5p Serum HCCs (n = 261) vs. HCs 
(n = 173)
Downregulated 0.70 
(0.63–0.77)
48.9 82.2 [52]
miR-192-5p Serum HCCs (n = 261) vs. HCs 
(n = 173)
Downregulated 0.70 
(0.62–0.77)
71.9 75.6 [52]
miR-26a-5p Serum HCCs (n = 261) vs. HCs 
(n = 173)
Downregulated 0.76 
(0.70–0.82)
68.9 74.4 [52]
miR-206 Serum HCCs (n = 261) vs. CCs 
(n = 233)
Upregulated 0.69 
(0.62–0.77)
77.8 68.9 [52]
miR-143-3p Serum HCCs (n = 261) vs. CCs 
(n = 233)
Upregulated 0.66 
(0.60–0.73)
60.7 72.7 [52]
miR-433-3p Serum HCCs (n = 261) vs. CCs 
(n = 233)
Upregulated 0.64 
(0.58–0.71)
56.4 67.4 [52]
miR-1228-5p Serum HCCs (n = 261) vs. CCs 
(n = 233)
Upregulated 0.54 
(0.47–0.61)
66.7 47 [52]
miR-199a-5p Serum HCCs (n = 261) vs. CCs 
(n = 233)
Downregulated 0.59 
(0.52–0.66)
59.3 57.6 [52]
miR-122-5p Serum HCCs (n = 261) vs. CCs 
(n = 233)
Downregulated 0.75 
(0.69–0.81)
48.9 90.2 [52]
miR-192-5p Serum HCCs (n = 261) vs. CCs 
(n = 233)
Downregulated 0.69 
(0.62–0.75)
54.8 83.3 [52]
miR-26a-5p Serum HCCs (n = 261) vs. CCs 
(n = 233)
Downregulated 0.74 
(0.68–0.81)
60.7 90.9 [52]
miR-16 Serum HCCs (n = 105) vs. CTLs 
(n = 188)
Downregulated / 72.1 88.8 [14]
miR-199 Serum HCCs (n = 105) vs. CTLs 
(n = 188)
Downregulated / 62.9 93.5 [14]
miR-199a Serum HCCs (n = 105) vs. CTLs 
(n = 188)
Downregulated / 78.1 64.5 [14]
miR-375 Serum HCCs (n = 78) vs. HCs 
(n = 156)
Downregulated 0.64 
(0.56–0.74)
/ / [53]
miR-199a-3p Serum HCCs (n = 78) vs. HCs 
(n = 156)
Downregulated 0.88 
(0.83–0.94
/ / [53]
miR-30c-5p Plasma HCCs (n = 8) vs. CTLs 
(n = 86)
Upregulated / / / [54]
miR-223-3p Plasma HCCs (n = 8) vs. CTLs 
(n = 86)
Downregulated / / / [54]
miR-202c-3p Plasma HCCs (n = 8) vs. CTLs 
(n = 86)
Upregulated / / / [54]
miR-17-57 Plasma HCCs (n = 8) vs. CTLs 
(n = 86)
Upregulated / / / [54]
miR-4651 Serum AHCCs (n = 279) vs. HCs 
(n = 338)
Upregulated 0.89 
(0.86–0.92)
78.1 99.1 [55]
miR-4651 Serum AHCCs (n = 279) vs. AHCs 
(n = 292)
Upregulated 0.82 
(0.78–0.85)
78.1 85.3 [55]
miR-4651 Serum AHCCs (n = 279) vs. ALCs 
(n = 32)
Upregulated 0.80 
(0.71–0.88)
78.1 81.2 [55]
Hepatocellular Carcinoma - Advances in Diagnosis and Treatment108
MicroRNAs Source Diagnostic relevance Expression level AUC 
(95% CI)
Sen 
(%)
Spe 
(%)
Refs
miR-4651 Serum AHCCs (n = 279) vs. CTLs 
(n = 662)
Upregulated 0.85 
(0.82–0.88)
78.1 92.1 [55]
miR-143 Serum HCCs (n = 131) vs. HCs 
(n = 122)
Downregulated 0.83 80.3 82.4 [56]
miR-125b Plasma HCCs (n = 64) vs. HCs 
(n = 56)
Downregulated 0.89 90.0 80.0 [57]
miR-125b Plasma HCCs (n = 64) vs. CHBs 
(n = 63)
Downregulated 0.96 90.0 90.0 [57]
miR-125b Plasma HCCs (n = 64) vs. CCs 
(n = 59)
Downregulated 0.96 90.0 90.0 [57]
miR-150 Serum HCCs (n = 120) vs. CHBs 
(n = 110)
Downregulated 0.88 
(0.84–0.93)
79.1 76.5 [58]
miR-150 Serum HCCs (n = 120) vs. HCs 
(n = 120)
Downregulated 0.93 
(0.90–0.96)
82.5 83.7 [58]
miR-106b Plasma HCCs (n = 47) vs. CTLs 
(n = 61)
Upregulated 0.81 0.7 0.8 [59]
miR-200a Serum HCCs (n = 22) vs. HCs 
(n = 15)
Downregulated 0.82 
(0.69–0.97)
/ / [60]
miR-200a Serum HCCs (n = 22) vs. CCs 
(n = 22)
Downregulated 0.73 
(0.56–0.89)
/ / [60]
miR-143 Serum HCCs (n = 95) vs. CHCs 
(n = 118)
Upregulated 0.62 
(0.51–0.76)
78.0 64.0 [46]
miR-215 Serum HCCs (n = 95) vs. CHCs 
(n = 118)
Upregulated 0.80 
(0.67–0.95)
78.0 89.0 [46]
miR-143 Serum HCCs (n = 95) vs. HCs 
(n = 127)
Upregulated 0.80 
(0.68–0.92)
78.0 89.0 [46]
miR-215 Serum HCCs (n = 95) vs. HCs 
(n = 127)
Upregulated 0.82 
(0.72–0.97)
80.0 91.0 [46]
miR-101 Serum HCCs (n = 67) vs. HCs 
(n = 30)
Downregulated 0.79 
(0.69–0.87)
76.1 70.0 [61]
miR-483-5p Serum HCCs (n = 49) vs. HCs 
(n = 49)
Upregulated 0.91 75.5 89.8 [62]
miR-122a Plasma HCCs (n = 85) vs. HCs 
(n = 85)
Downregulated 0.71 70.6 67.1 [63]
miR-618 Urine HCCs (n = 32) vs. CTLs 
(n = 74)
Upregulated 0.66 64.0 68.0 [47]
miR-650 Urine HCCs (n = 32) vs. CTLs 
(n = 74)
Downregulated 0.65 72.0 58.0 [47]
miR-126 tumor 
tissue
HCCs vs. CAs Upregulated / / / [48]
Abbreviation: miR, microRNA; HCCs, cases with hepatocarcinoma; CTLs, non-HCC controls (including healthy control 
and other nontumor controls); HCs, healthy controls; CCs, controls with liver cirrhosis; CHBs, patients with chronic 
hepatitis B; CLDs, cases with nontumor chronic liver diseases; Sen, sensitivity; Spe, specificity; AUC, the area under the 
receiver operating characteristic curve; CI, confidence interval; Refs, references.
Table 1. The microRNAs as diagnostic biomarkers for hepatocarcinoma.
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other serum microRNAs, such as microRNA-15b, microRNA-130b, miR-143, and miR-215, 
are additional potential biomarkers that are significantly dysregulated in hepatocarcinoma 
[45, 46]. Noticeably, these biomarkers also exhibit their diagnostic potential for patients with 
early-stage hepatocarcinoma and/or negative-status AFP [45, 46].
Recently, some evidence has also exhibited that microRNAs in urine samples and liver tissues 
have screening potential for hepatocarcinoma (Table 1). Actually, the detection of five deregu-
lated microRNAs, including microR-618, microRNA-625, microRNA-650, microRNA-532, and 
miR-516-5P, in the urine samples has already been used for screening patients with the early and 
small hepatocarcinoma from these with risk factors such as chronic virus hepatitis, liver cirrho-
sis, and dysplasia [47]. Barshack et al. [48] investigated differential diagnosis potential of microR-
NAs for discriminating hepatocarcinoma from metastatic tumors in the liver using custom 
microarray expression technique. In their study, they tested the distributed features of microR-
NAs among 144 tumor samples with or without metastatic adenocarcinoma and similar hepato-
carcinoma in the morphology and immune types and found that microR-141 and microR-200c 
can promote non-hepatic epithelial phenotypes while microRNA-126 displays hepatic epithelial 
phenotypes. Higher expression of microRNA-126 is further shown in these tissue samples with 
hepatocarcinoma. Therefore, the change profiles of microRNAs in body fluids (such as urine) 
and tumor tissues may represent a kind of gold biomarkers for such cancers as liver carcinoma.
However, the specificity of a single microRNA identifying hepatocarcinoma is relatively poor. 
For example, the serum level of aforementioned liver-specific microRNA-122 is upregulated 
not only among cases with hepatocarcinoma but also among these with chronic virus hepati-
tis, liver cirrhosis, and fatty liver diseases caused by alcohol or non-alcohol [49, 50]. Evidence 
has shown that serum microRNA-122 does not discriminate patients with hepatocarcinoma 
from these with chronic hepatitis, although higher expression is observed among cancer cases 
[40, 41]. This indicates that more investigations on the basis of large size of samples and the 
prospective randomized controlled trials should help us for addressing these concerns.
3.2. Diagnostic potential of microRNA panel for hepatocarcinoma
Because hepatocarcinoma is a multifactor-induced highly complex malignant disease with 
heterogeneous feature, a combination of multiple microRNAs in place of a single microRNA 
may have higher accuracy for hepatocarcinoma discrimination. Several circulating microRNA 
panels have been reported to have higher early diagnostic value for hepatocarcinoma (Table 2) 
[47, 51, 52, 64–70]. For example, Lin et al. [70] preformed a three-stage study consisting of the 
discovery stage (including 6 cases with hepatocarcinoma and 8 cases with chronic hepati-
tis B), the training stage (including 108 cases with hepatocarcinoma, 51 cases with chronic 
hepatitis B, 47 cases with liver cirrhosis, and 51 healthy controls), and the validation stage 
(including 229 patients with hepatocarcinoma and 424 controls with or with nontumor liver 
diseases). In the first stage, they identified 31 different serum microRNAs between individuals 
with hepatocarcinoma and those with chronic hepatitis B using the TaqMan Array technique. 
Next, they validated these different microRNAs and constructed diagnostic panel contain-
ing miR-29a, miR-29c, miR-133a, miR-143, miR-145, miR-192, and miR-505 on the basis of 
logistic regression model. Finally, the established serum microRNA panel was tested among 
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individuals from the training and validation cohorts. These data identified seven microR-
NAs and constructed a serum microRNA panel with an increasing diagnostic accuracy for 
hepatocarcinoma [AUC = 0.826 (0.771–0.880) for training set and 0.817 (0.769–0.865) and 0.884 
(0.818–0.951) for two different validation sets, respectively]. Interestingly, a nest case-control 
study has further proved that this panel could be used to detect preclinical hepatocarcinoma 
as well as small-size, early-stage, and α-fetoprotein-negative disease.
MicroRNA panel Source AUC (95% 
CI)
Sen (%) Spe 
(%)
Diagnostic 
relevance
Refs
miR-10b + miR-106b + miR-181a Serum 0.94 
(0.89–0.99)
/ / HCCs (n = 27) vs. 
HCs (n = 50)
[51]
miR-10b + miR-106b + miR-181a Serum 0.91 
(0.80–0.97)
/ / HCCs (n = 27) vs. 
CLDs (n = 31)
[51]
miR-206 + miR-143-3p + miR-
433-3p + miR-1228-5p + miR-
199a-5p + miR-122-5p + miR-
192-5p + miR-26a-5p
Serum 0.89 
(0.85–0.94)
82.8 83.3 HCCs (n = 261) vs. 
HCs (n = 173)
[52]
miR-206 + miR-143-3p + miR-
433-3p + miR-1228-5p + miR-
199a-5p + miR-122-5p + miR-
192-5p + miR-26a-5p
Serum 0.89 
(0.84–0.94)
81.6 84.6 HCCs (n = 261) vs. 
CCs (n = 233)
[52]
miR-122 + miR-192 + miR-21 + miR-
223 + miR-26a + miR-27a + miR-801
Plasma 0.86 
(0.83–0.90)
68.6 90.1 HCCs (n = 204) vs. 
CTLs (n = 303)
[64]
miR-122 + miR-192 + miR-21 + miR-
223 + miR-26a + miR-27a + miR-801
Plasma 0.89 
(0.85–0.92)
81.8 83.5 HCCs (n = 196) vs. 
CTLs (n = 194)
[64]
miR-27b-3p + miR-192-5p Serum 0.84 
(0.78–0.89)
0.7 0.9 HCCs (n = 91) vs. 
CTLs (n = 91)
[65]
miR-92-3p + miR-107 + miR-3126-5p Serum 0.97 
(0.95–0.99)
/ / HCCs (n = 115) vs. 
HCs (n = 40)
[66]
88-miRNA Serum 1.00 
(0.97–1.00)
100.0 99.2 HCCs (n = 261) vs. 
CCs (n = 233)
[67]
miR214-5p + miR-125b + miR-1269 + miR-
375
Serum 0.95 96.9 83.2 HCCs (n = 224) vs. 
HCs (n = 84)
[68]
miR-122 + miR-885-5p + miR-29b Serum 1.00 / / HCCs (n = 192) vs. 
HCs (n = 96)
[69]
miR-29a + miR-29c + miR-133a + miR-
143 + miR-145 + miR-192 + miR-505
Serum 0.82 
(0.77–0.87)
74.5 89.9 HCCs (n = 153) vs. 
CTLs (n = 199)
[70]
miR-29a + miR-29c + miR-133a + miR-
143 + miR-145 + miR-192 + miR-505
Serum 0.88 
(0.82–0.95)
85.7 91.1 HCCs (n = 49) vs. 
CTLs (n = 90)
[70]
miR-618 + miR-650 Urine 0.69 58.0 75.0 HCCs (n = 32) vs. 
CTLs (n = 74)
[47]
Abbreviation: miR, microRNA; HCCs, cases with hepatocarcinoma; CTLs, non-HCC controls (including healthy control 
and other nontumor controls); HCs, healthy controls; CCs, controls with liver cirrhosis; CHBs, patients with chronic 
hepatitis B; CLDs, cases with nontumor chronic liver diseases; Sen, sensitivity; Spe, specificity; AUC, the area under the 
receiver operating characteristic curve; CI, confidence interval; Refs, references.
Table 2. The microRNA panel as diagnostic biomarkers for hepatocarcinoma.
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Similarly, Jiang et al. [59] and Zhou et al. [64] also attempted to identify possible combination of 
different microRNAs for increasing diagnostic accuracy of hepatocarcinoma on the basis of dif-
ferent controls with or without liver diseases. They found that the panel consisting of miR-10b, 
miR-106b, and miR-181a as well as the combination of miR-122, miR-192, miR-21, miR-223, miR-
26a, miR-27a, and miR-801 can improve detection of hepatocarcinoma. These reports indicate 
that the panel of microRNAs may have better performance than a single-microRNA assay.
3.3. Diagnostic potential of microRNAs binding with AFP for hepatocarcinoma
AFP has been regarded as the most important marker for hepatocarcinoma screening and 
diagnosis, ever since it was identified in the peripheral blood samples from patients with 
hepatocarcinoma in 1964 [8, 71, 72]. However, this marker is relatively unsatisfactory because 
of its low sensitivity and specificity. This is mainly because only 60–80% of cases with hepa-
tocarcinoma show positive AFP, whereas about 40% of cirrhotic patients also exhibit different 
degree increasing level of serum AFP [73, 74]. Thus, AFP may not be a reliable hepatocar-
cinoma marker, especially for early-stage and/or AFP-negative hepatocarcinoma. On the 
basis of low sensitivity and specificity of AFP for hepatocarcinoma diagnosis, the American 
Association for the Study of Liver Disease Practice Guidelines has thrown it away for prog-
nostic surveillance and tumor diagnosis [75]. However, recent studies have displayed that the 
combination of AFP in the peripheral blood and microRNAs in body fluids may improve the 
sensitivity and specificity of hepatocarcinoma diagnosis and increase their diagnostic poten-
tial [14, 47, 55, 58, 65–67, 69, 70, 76].
For example, Wu et al. [55] investigated the joint diagnostic value of serum microRNA-4651 
and AFP for hepatocarcinoma in 279 hepatocarcinoma patients, 324 controls with liver 
injury, and 338 healthy controls. Their results imply that serum microRNA-4651 has higher 
expression level among cases with hepatocarcinoma (AUC of 0.85; sensitivity of 78.1% and 
specificity of 92.1%); this increasing expression also displays higher diagnostic potential than 
AFP at cutoff of 20 ng/mL (AFP20) (AUC = 0.80, sensitivity = 61.3%, and specificity = 98.8%) 
and of 400 ng/mL (AFP400) (AUC = 0.72, sensitivity = 43.0%, and specificity = 100.0%). 
Noticeably, the combination of serum microRNA-4651 with AFP significantly improves the 
discrimination power between patients with hepatocarcinoma and with chronic nontumor 
liver injury (AUC = 0.90, sensitivity = 83.2%, and specificity = 97.1%). Similar findings have 
also been observed in the analyses of combination of serum AFP and other microRNAs, 
such as miR-29a, miR-29c, miR-133a, miR-143, miR-145, miR-192, miR-505, miR-16, miR-195, 
and miR-199a [14, 47, 58, 65–67, 69, 70, 76]. Altogether, these data suggest that the combina-
tion of microRNAs with AFP may improve diagnostic potential of hepatocarcinoma.
4. Prognostic potential of microRNA for hepatocarcinoma
In the past decades, growing evidence has exhibited that microRNAs can act as prognostic bio-
markers for hepatocarcinoma [56, 77–101], and Table 3 summarizes these significantly affecting 
hepatocarcinoma outcomes. Functionally, the microRNAs affect hepatocarcinoma prognosis 
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MicroRNAs Source Expression level Prognostic significance HR 
(95%CI)
Refs
miR-122 Serum Upregulated Increasing levels correlate with 
poor OS
OS, 0.08 
(0.03–0.22)
[120]
miR-1 Serum Upregulated Increasing levels correlate with 
poor OS
OS, 0.45 
(0.23–0.86)
[121]
miR-122 Serum Upregulated Correlated with clinical 
chemistry parameters of hepatic 
necroinflammation, liver function, 
and synthetic capacity
/ [121]
miR-221 Serum Upregulated (1) Correlated with tumor size, 
cirrhosis, and tumor stage; (2) 
increasing levels decreased 
survival rate
/ [122]
miR-4651 Serum Upregulated Increasing levels correlate with 
poor OS and RFS
OS, 2.67 
(1.61–4.42)
RFS, 3.62 
(1.49–8.81)
[55]
miR-1268a Tumor 
tissues
Upregulated Increasing levels correlate with 
poor OS and RFS
OS, 2.44 
(1.82–3.23)
RFS, 2.86 
(2.08–3.85)
[115]
miR-24 Tumor 
tissues
Upregulated Increasing levels correlate with 
poor OS and RFS
OS, 3.58 
(2.34–5.46)
RFS, 4.75 
(2.66–8.47)
[77]
miR-429 Tumor 
tissues
Upregulated Increasing levels correlate with 
poor OS and RFS
OS, 4.64 
(2.56–8.41)
RFS, 6.94 
(3.19–15.08)
[78]
miR-143 Serum Downregulated Decreasing levels correlate with 
poor OS and RFS
/ [56]
miR-9 Tumor 
tissues
Upregulated Increasing levels correlate with 
poor OS and RFS
/ [123]
miR-92b Tumor 
tissues, 
serum
Upregulated Increasing levels promoting tumor 
metastasis
/ [102]
miR-150 Serum Downregulated Increasing levels correlate with 
poor OS
0.45 
(0.23–0.85)
[58]
miR-21 Serum Upregulated Increasing levels correlate with 
poor OS
2.23 
(1.33–3.74)
[76]
20-miRNA 
signature
Tumor 
tissues
10 downregulated 
and 20 upregulated 
miRNAs
6 were risk factors and 14 were 
protective factors
OS, 2.75 
(1.58–4.79)
[124]
miR-221 Tumor 
tissues
Upregulated Increasing expression promotes 
metastasis-free survival
/ [125]
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MicroRNAs Source Expression level Prognostic significance HR 
(95%CI)
Refs
miR-96 Tumor 
tissues
Upregulated Increasing expression correlates 
with poor RFS
/ [126]
miR-92a Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor RFS
RFS, 1.60 
(1.00–2.50)
[79]
miR-22 Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor RFS
/ [80]
miR-500 Serum Upregulated Decreasing expression correlates 
with tumor resected
/ [127]
miR-375 Tumor 
tissues
/ Decreasing expression correlates 
with poor RFS
RFS, 3.273 [81]
miR-148b Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor OS
OS, 1.86 
(1.23–2.98)
[82]
miR-101 Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor OS and RFS
RFS, 2.56 
(1.32–5.69)
OS, 3.27 
(1.18–6.92)
[83]
miR-19a Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor OS and RFS
/ [84]
miR-210 Tumor 
tissues
Upregulated Increasing expression correlates 
with poor OS
/ [80]
miR-224 Tumor 
tissues
Upregulated Increasing expression correlates 
with poor OS and RFS
/ [85]
miR-29 Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor and RFS
/ [86]
miR-139-5p Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor OS
/ [87]
miR-1 Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor OS and RFS
OS, 2.79 [88]
miR-199b-5p Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor OS
/ [89]
miR-130b Tumor 
tissues
Upregulated Increasing expression correlates 
with poor OS and RFS
RFS, 4.00 
(1.58–7.90)
OS, 2.52 
(1.02–7.90)
[90]
miR-9 Tumor 
tissues
Upregulated Increasing expression correlates 
with poor OS and RFS
/ [91]
miR-25 Tumor 
tissues
Upregulated Increasing expression correlates 
with poor OS and RFS
RFS, 1.62
OS, 2.18
[92]
let-7 Tumor 
tissues
Upregulated Increasing expression correlates 
with poor OS
/ [93]
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via the following pathways: (1) promoting cancerous growth and proliferation [77, 78, 80, 83, 
89, 98, 99, 102–113], (2) inhibiting cancerous apoptosis [77, 78, 86, 99, 101, 107–109, 111, 112, 
114], (3) increasing microvessel density in the tumor tissues [77, 115], (4) affecting cell cycles 
[24, 25, 27, 28, 116–119], (5) increasing the risk of tumor metastasis [77, 115], and (6) decreasing 
the sensitivity of cancer cells to anticancer drugs [115]. For example, Lu et al. [115] investigated 
the prognostic potential of microRNA-1268a for hepatocarcinoma in 411 patients with hepato-
carcinoma. Their results imply that microRNA-1268a expression in the cancerous tissues is sig-
nificantly related to tumor features including tumor volume, stage and grade, and microvessel 
density. Results from multivariable factors analyses based on Cox regression models show that 
microRNA-1268a expression is independent of other known prognostic factors for hepatocarci-
noma. Furthermore, transarterial chemoembolization (TACE) treatment can improve the prog-
nosis of hepatocarcinoma patients with low microRNA-1268a expression, but not for those 
with high microRNA-1268e expression. These data imply that the dysregulation of microRNA-
1268a can modify the response of cancer cells to antidrugs. Their following studies prove that 
upregulated microRNA-1268a inhibited while its downregulation enhanced doxorubicin 
MicroRNAs Source Expression level Prognostic significance HR 
(95%CI)
Refs
miR-30a Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor RFS
RFS, 3.2 
(1.5–6.8)
[94]
miR-99a Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor RFS
RFS, 1.60 
(1.00–2.50)
[79]
miR-106b Tumor 
tissues
Upregulated Increasing expression correlates 
with poor OS
OS, 2.00 
(1.13–6.98)
[95]
miR-130a Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor OS
OS, 2.22 
(1.10–4.46)
[96]
miR-19b Tumor 
tissues
/ Increasing expression correlates 
with good OS
OS, 0.45 
(0.24–0.85)
[97]
miR-148a Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor OS
/ [98]
miR-372 Tumor 
tissues
Upregulated Increasing expression correlates 
with poor OS and RFS
RFS, 6.83
OS, 9.53
[99]
miR-630 Tumor 
tissues
Downregulated Increasing expression correlates 
with good OS and RFS
OS, 0.71 
(0.26–1.92)
RFS, 0.66 
(0.33–1.35)
[100]
miR-100 Tumor 
tissues
Downregulated Decreasing expression correlates 
with poor OS
OS, 1.66 
(1.32–2.82)
[101]
Abbreviation: miR, microRNA; OS, overall survival; RFS, tumor recurrence-free survival; HR, hazard ratio; CI, 
confidence interval; Refs, references.
Table 3. The microRNAs as prognostic biomarkers for hepatocarcinoma.
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(an anticancer drug)-induced the death of tumor cells. Similarly, Liu et al. [77] and Huang et al. 
[78] investigated the roles of microRNAs, such as microRNA-24 and microRNA-429, in the 
tumorigenesis of liver cancer on the basis of analyses of hepatocarcinoma samples and genic 
toxicity induced by aflatoxin B1 and found the dysregulation of these microRNAs increased 
microvessel density and mutation frequency of TP53 gene possibly resulting from the loss of 
DNA repair capacity. Taken together, these reports indicate that microRNAs in body fluids 
and cancerous tissues may be important candidate biomarkers for hepatocarcinoma prognosis.
5. Further direction
In the past decades, the advance in pathological mechanisms of microRNAs regulating tumor-
igenesis and procession of hepatocarcinoma holds great promise for identifying whether 
microRNAs in body fluids (such as blood and urine) act as novel early diagnostic and prog-
nostic biomarkers for this malignancy. However, we are still far from a comprehensive view 
of this kind of potentials. Although some hepato-specific microRNAs have been identified, 
microRNAs in body fluids may be from hemocytes and vascular endothelial cells and oth-
ers from tissues and organs with high blood flow as well as hepatocarcinoma. This kind of 
heterogeneous origin indicates that the dysregulation of tumor-specific microRNA signa-
tures may be concealed by microRNAs from other origins. Furthermore, well-standardized 
protocols of testing microRNAs have not been constructed or confirmed on the basis of the 
prospective, randomized controlled trials. Disclosing the different diagnostic and prognostic 
potential of microRNAs will greatly benefit our constructing high accurate diagnostic and 
prognostic models for hepatocarcinoma and will shed important light on the early diagnosis, 
tumor monitoring, and prognosis prediction for individuals with risk factors.
6. Summary
To conclude, the advances in technologies, including microarray PCR technology, high-
throughput sequencing, and mass spectrometry, make it possible to identify new markers for 
hepatocarcinoma diagnosis and prognosis. On the whole, the microRNAs are a class of attrac-
tive markers and may replace known traditional serum markers such as AFP on the basis of 
the following reasons. First, because many circulating microRNAs is highly stable and readily 
detected in patients with hepatocarcinoma, they may have higher diagnostic potential (with 
high AUCs, sensitivity, and specificity) for hepatocarcinoma than AFP. Second, some microR-
NAs appear in the urine and can be utilized for screening patients with high-risk factors of 
hepatocarcinoma. Third, some dysregulated microRNAs in the body fluids can change with 
the different stages of hepatocarcinoma, indicative of their potential in monitoring tumor 
recurrence. Finally, different expressions of microRNAs are useful for treatment strategies 
such as TACE selection. Taken together, the dysregulated microRNAs in body fluids (includ-
ing urine and blood) may be a kind of promised biomarkers for liver carcinoma diagnosis and 
prognosis because they are early detected and easily monitored.
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However, there are several issues to be noted. First, research on the diagnostic and prognostic 
potential of microRNAs is still in the early stages, and challenges are noticeable in the clinical 
utilization of significant microRNAs. Second, in spite of these biomarkers that are discussed 
well, their therapeutic potential still remains unclear. Finally, although the diagnostic and 
prognostic potential of microRNAs is well evaluated on the basis of retrospective case-control 
studies, results from the prospective, randomized controlled trials are absent. Finally, because 
of the polygenic feature for hepatocarcinoma development, it is essential for a panel of bio-
markers to determine high-risk individuals. Thus, the advances in the fields of microRNAs 
including their origins, stability, detection strategies, variant characteristics, and biofunctions 
in hepatocarcinoma will progress microRNAs in body fluids to become possible tools for 
hepatocarcinoma diagnosis and prognosis in the future.
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